이효바이오싸이언스

비상장계속사업자

Leehyo Bioscience Co. Ltd.

이효철

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

이효바이오싸이언스

Business Reg. No. 2158159247 · CEO 이효철

I.Investment Overview

Target이효바이오싸이언스 (2158159247)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명이효바이오싸이언스
영문명Leehyo Bioscience Co. Ltd.
대표자이효철
사업자등록번호2158159247
법인등록번호1101111340788
설립일1996.05.01

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW320.42021353.220223092023287.62024354.82025
영업이익100M KRW29.3202122.22022-20.72023-12.22024-0.52025
순이익100M KRW23.6202117.92022-20.22023-12.320242.32025
Item20252024202320222021
자산총계160.9억원136.7억원135.8억원160.2억원167.5억원
부채총계72.8억원50.9억원37.7억원41.8억원67.1억원
자본총계88.1억원85.9억원98.1억원118.3억원100.4억원
매출액354.8억원287.6억원309억원353.2억원320.4억원
영업이익-4,712만원-12.2억원-20.7억원22.2억원29.3억원
순이익2.3억원-12.3억원-20.2억원17.9억원23.6억원

VI.Financial Ratios

FY2025 basis

-0.13%

영업이익률

0.64%

순이익률

1.4%

ROA

2.56%

ROE

82.6%

부채비율

54.76%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

이효바이오싸이언스 투심보고서 | Alpha Lenz